Skip to Content

GSK takes minority stake in new spin out Autifony Therapeutics

Issued: Monday 22 August 2011, London UK

GlaxoSmithKline plc today announced that its wholly-owned subsidiary Glaxo Group Limited (GSK) will receive a 25.4% minority equity stake, representing a £1,250,000 investment, in Autifony Therapeutics Limited, a UK-based biotechnology start up created through a funding round of up to £10 million alongside investors Imperial Innovations and SV Life Sciences.

Under the terms of the agreement, Autifony will issue 850,000 A ordinary shares to GSK in exchange for a number of pre-candidate voltage-gated ion channel modulator compounds and associated patent applications and data for development in hearing loss, as well as 571,429 Series A preferred shares in recognition of £400,000 worth of development work funded by GSK on behalf of Autifony.

GSK will also be eligible to receive a further 550,000 A ordinary shares on achievement of a pre-determined milestone, at which time there will be a further investment by the existing consortium and GSK will then own 13.2% of Autifony on a fully diluted basis.

GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit


GlaxoSmithKline enquiries:



UK Media enquiries:

David Mawdsley

(020) 8047 5502


Stephen Rea

(020) 8047 5502


Sarah Spencer

(020) 8047 5502


Janet Morgan

(020) 8047 5502


David Daley

(020) 8047 5502




US Media enquiries:

Nancy Pekarek

(919) 483 2839


Mary Anne Rhyne

(919) 483 2839


Kevin Colgan

(919) 483 2839


Jennifer Armstrong

(919) 483 2839




European Analyst/Investor enquiries:

Sally Ferguson

(020) 8047 5543


Gary Davies

(020) 8047 5503


Ziba Shamsi

(020) 8047 3289




US Analyst/ Investor enquiries:

Tom Curry

(215) 751 5419


Jeff McLaughlin

(215) 751 7002


GlaxoSmithKline cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2010.

Posted: August 2011

Recommended for you

View comments